for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

51.61USD

Change

0.83(+1.63%)

Volume

2,523,275

Today's Range

51.23

 - 

51.97

52 Week Range

42.49

 - 

60.77

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bristol-Myers Squibb Says 5-Year Results For Opdivo In Combination With Yervoy Showed Durable Long-Term Survival Benefits

Sept 28 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::5-YEAR RESULTS FOR OPDIVO IN COMBINATION WITH YERVOY SHOWED DURABLE LONG-TERM SURVIVAL BENEFITS IN PATIENTS WITH ADVANCED MELANOMA.SAFETY PROFILE FOR OPDIVO PLUS YERVOY WAS CONSISTENT WITH PRIOR FINDINGS.RESULTS REPRESENT LONGEST FOLLOW-UP TO DATE FOR DUAL IMMUNO-ONCOLOGY (I-O) THERAPY IN A PHASE 3, RANDOMIZED, CONTROLLED TRIAL.

Bristol-Myers Squibb Gets Positive CHMP Opinion Recommending Approval Of Opdivo 4-Week Dosing Schedule

Sept 24 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB - RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF OPDIVO 4-WEEK DOSING SCHEDULE FOR AN ADJUVANT MELANOMA TREATMENT.

Bristol-Myers Squibb Says On September 11, Size Of Board Was Increased To Fourteen

Sept 12 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB CO - ON SEPTEMBER 11, SIZE OF BOARD OF DIRECTORS WAS INCREASED TO FOURTEEN.

Bristol-Myers Squibb Board Announces Election Of Three New Directors

Sept 11 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB BOARD ANNOUNCES ELECTION OF THREE NEW DIRECTORS.BRISTOL-MYERS SQUIBB CO - MICHAEL BONNEY, JULIA HALLER AND PHYLLIS YALE TO JOIN BMS BOARD AS INDEPENDENT DIRECTORS.

Bristol‑Myers Squibb Announces Dividend

Sept 11 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL‑MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY ONE CENTS ($0.41) PER SHARE.

Bristol-Myers Squibb Says Phase 3 Opdivo Checkmate-548 Trial Did Not Meet One Of Its Primary Endpoints

Sept 5 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB PROVIDES UPDATE ON PHASE 3 OPDIVO (NIVOLUMAB) CHECKMATE -548 TRIAL IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA MULTIFORME.BRISTOL-MYERS SQUIBB CO - DATA MONITORING COMMITTEE RECOMMENDED THAT TRIAL CONTINUE AS PLANNED.BRISTOL-MYERS SQUIBB CO - COMPANY REMAINS BLINDED TO ALL STUDY DATA.BRISTOL-MYERS SQUIBB CO - CHECKMATE -548 DID NOT SHOW STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL.BRISTOL-MYERS SQUIBB CO - DATA MONITORING COMMITTEE RECOMMENDED THAT TRIAL CONTINUE TO ALLOW OTHER PRIMARY ENDPOINT TO MATURE.BRISTOL-MYERS SQUIBB CO - PHASE 3 OPDIVO (NIVOLUMAB) CHECKMATE -548 TRIAL DID NOT MEET ONE OF ITS PRIMARY ENDPOINTS.

Presage Announces Collaboration With Bristol-Myers Squibb For Phase O Studies Of Novel Cancer Agents Utilizing Civo Technology

Aug 27 (Reuters) - Presage Biosciences ::PRESAGE ANNOUNCES COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR PHASE O STUDIES OF NOVEL CANCER AGENTS UTILIZING CIVO™ TECHNOLOGY.PRESAGE BIOSCIENCES - ENTERED INTO A RESEARCH COLLABORATION WITH BRISTOL-MYERS SQUIBB COMPANY.BRISTOL-MYERS SQUIBB CO - SPECIFIC TERMS AND DETAILS REGARDING COLLABORATION ARE UNDISCLOSED.PRESAGE BIOSCIENCES SAYS TO EVALUATE EARLY STAGE ONCOLOGY TARGETS IN PHASE 0 TRIALS.PRESAGE BIOSCIENCES SAYS SPECIFIC TERMS AND DETAILS REGARDING COLLABORATION ARE UNDISCLOSED.

Catalent Q4 Earnings Per Share $0.44

Aug 27 (Reuters) - Catalent Inc <CTLT.N>::CATALENT, INC. REPORTS FOURTH QUARTER FISCAL 2019 RESULTS.Q4 EARNINGS PER SHARE $0.44.SEES FY 2020 REVENUE $2.78 BILLION TO $2.88 BILLION.Q4 REVENUE $725.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $721 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.64 -- REFINITIV IBES DATA.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.70.FOR FISCAL 2020 EXPECTS ADJUSTED EBITDA IN RANGE OF $700 MILLION TO $730 MILLION AND ADJUSTED NET INCOME IN RANGE OF $300 MILLION TO $330 MILLION.CATALENT - ANNOUNCED AGREEMENT TO BUY BRISTOL-MYERS SQUIBB'S ORAL SOLID, BIOLOGICS, & STERILE PRODUCT MANUFACTURING & PACKAGING FACILITY IN ANAGNI, ITALY.FY2020 REVENUE VIEW $2.84 BILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CO HAD $3.0 BILLION IN TOTAL DEBT, AND $2.6 BILLION IN TOTAL DEBT NET OF CASH AND SHORT-TERM INVESTMENTS.

Amgen On Anticipated FTC Concerns Says Highly Confident About Deal For Otezla

Aug 26 (Reuters) - Amgen Inc <AMGN.O>::AMGEN EXECUTIVE ON ANTICIPATED FTC CONCERNS SAYS HIGHLY CONFIDENT ABOUT DEAL FOR OTEZLA: CONF. CALL.

Amgen sees SG&A, R&D expenses up in 2020 after Otezla deal

Aug 26 (Reuters) - Amgen <AMGN.O>::EXEC SEES 2020 NON-GAAP SG&A EXPENSES UP $600-700 MILLION DUE TO ONGOING COST OF OTEZLA-CONF. CALL.EXEC SEES 2020 NON-GAAP RESEARCH AND DEVELOPMENT OPERATING EXPENSES UP $500 MILLION -CONF. CALL.EXEC SEES 2020 SHARE REPURCHASES CONSISTENT WITH 2015-2018 REPURCHASES, EXCLUDING 2018 TENDER-CONF. CALL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up